Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing

Nucleic Acid Insights 2024; 1(5), 185–190

DOI: 10.18609/nai.2024.023

Published: 3 June
Jeske Smink

David McCall, Senior Editor, Nucleic Acid Insights, speaks to Jeske Smink, Senior Director, Head of Drug Substance, about Silence Therapeutics’ platform-based approach to developing targeted short interfering RNA-based therapies. They discuss the current state-of-the-art in oligonucleotide manufacturing and CMC, and explore the emerging alternatives to the traditional solid-phase synthesis approach.